Top 2% Biotech Avidity Tumbles Despite 'Positive' Results In Treating Muscular Dystrophy
Top-notch biotech stock Avidity tumbled Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.
Top-notch biotech stock Avidity tumbled Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.